Study of the efficacy of topical 25% benzyl benzoate versus 5%permethrin in patients with scabies

Phase 3

• Conditions: B86; Scabies

• Registration Number: DRKS00031062
• Lead Sponsor: K f. Dermatologie und Allergologie Salzburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-18
• Study Completion: 2023-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

Scabies with light microscopic mite detection.
- Age: from 12 years of age (treatment by parent until physical/cognitive
development allows self-treatment)

Exclusion Criteria

- Scabies norvegica/crustosa
- Pre-treatment of creams/emulsions containing benzyl benzoate (Antiscabiosum® 25%) in the last 3 weeks (from first application)
- Application of creams containing permethrin (e.g. Infectoscab® 5%) during the last 3 weeks (from first application)
- Use of oral ivermectin in the last 3 weeks.
-- EXCEPTION: Children from the age of 12 to 18 years or study participants with a high mite density (>5 mites with duct structures in the reflected light microscope field of view) may be treated with topical benzyl benzoate, topical benzyl benzoate, topical benzyl benzoate, topical benzyl benzoate
benzyl benzoate, topical permethrin or oral ivermectin may be included
- known hypersensitivity to the active ingredient benzyl benzoate or permethrin
- Patients who, because of their physical development or clinical condition, are unable to receive
Are unable to understand and correctly perform the treatment procedures
- Pregnancy and lactation
- Alcohol abuse, mental retardation
- Lack of willingness to comply/adhere to appointments as well as the
Study protocol, and lack of understanding of the German language.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy

Secondary Outcome Measures

Name	Time	Method
Tolerance